Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 540 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Samples Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection

NCT02330445
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PRTX-100
Drug
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 31, 2026, 5:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

NCT05455697
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions
Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Completed No phase listed Observational

Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia

NCT00050115
View directory record Official record
Conditions
Hepatitis-Associated Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT07110246
View directory record Official record
Conditions
BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions
Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 25 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

NCT07708961
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Taking of blood samples, Boostrix, Adacel
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years to 73 Years
Enrollment
1,954 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
37
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Completed No phase listed Observational

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

NCT04951154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Bronchoscopic Biopsy, Blood Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 31, 2026, 5:42 AM EDT
Terminated No phase listed Observational

MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

NCT05087888
View directory record Official record
Conditions
Brain Neoplasm
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 1 Interventional

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

NCT06209619
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography, Rituximab
Procedure · Drug · Biological
Lead sponsor
Nathan Denlinger
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

NCT05773274
View directory record Official record
Conditions
Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions
Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Not applicable Interventional

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

NCT06207864
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Biospecimen Collection, Return of Results, Survey Administration
Procedure · Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 1 Interventional

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

NCT07532525
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Pomalidomide
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Withdrawn Phase 1 Interventional

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

NCT05807126
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Magrolimab, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Costa Mesa, California • Orange, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT05688215
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quemliclustat, Zimberelimab
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Got Doxy- 'Flipping the Script' on STI PEP

NCT07215325
View directory record Official record
Conditions
Sexually Transmitted Infections (STI)
Interventions
Doxycycline monohydrate 200 mg, Observation
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

NCT06617455
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma
Interventions
Biospecimen Collection, Fezolinetant, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting No phase listed Observational

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

NCT01137643
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
biologic sample preservation procedure, cytology specimen collection procedure
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

NCT07393555
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
41
States / cities
Berkeley, California • Palo Alto, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

EMBRACE: Exercising Together

NCT06049355
View directory record Official record
Conditions
Breast Carcinoma, Prostate Carcinoma
Interventions
Exercise Intervention, Biospecimen Collection, Educational Intervention
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT05436418
View directory record Official record
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)

NCT05658471
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Toxicity, Cardiovascular Risk Factors
Interventions
Standardized Research E-Cigarette (SREC), Over the Counter E-Cigarette (EC), Biological Samples, Smoking-related Questionnaires
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 31, 2026, 5:42 AM EDT
Completed No phase listed Observational

SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

NCT01000558
View directory record Official record
Conditions
Lymphoma
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
203
States / cities
Mobile, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 137 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 31, 2026, 5:42 AM EDT
Recruiting Phase 1 Interventional

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

NCT06410248
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide, Triapine
Procedure · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 5:42 AM EDT